AstraZeneca PLC AZN
Open calendar →AstraZeneca PLC Ordinary Shares · Company · NYSE · Healthcare / Drug Manufacturers - General
Paper trade (simulated — no real money)
Fill: USD 171.4900 · FX 1 USD = 1.277900 SGD · about SGD 219.1471 per unitSign in to place simulated trades. USD fills are converted into the SGD portfolio at the displayed rate.
USD closing-price chart (daily close from yfinance · Last year)
USD 166.80 → 171.49 · 2.8%
Numbered dotted lines mark the filtered filings under Announcement Events below.
Price & SEC Filing History 23 Oct 2025 — 24 Oct 2026 (Last year)
Daily NYSE prices are sourced from yfinance. Yellow highlighting marks an intraday rise or a gap up between adjacent trading sessions. SEC acceptance times are converted to US Eastern time: pre-market filings appear below that day’s OHLCV row; filings accepted after the 09:30 ET open appear above it. The SEC does not publish an exact first-public-availability timestamp, so acceptance time is the best available proxy.
Date
Open
High
Low
Close
Volume
Weekend
171.2800
171.7500
169.5100
171.4900
3,666,259
95 · 6-K
After market open · 11:10 ET
ULTOMIRIS APPROVED IN US IN IGAN ↗
169.8600
173.9100
169.3200
172.5700
2,773,200
168.9100
169.8400
168.0900
168.4500
1,896,800
166.7700
169.2400
166.6600
168.8200
4,592,300
164.5100
166.1000
163.9100
163.9500
2,322,100
Weekend
Weekend
166.9700
167.1800
164.3700
165.4100
3,460,900
167.6900
169.8100
166.4900
166.6800
4,403,800
158.7100
162.7100
158.3100
162.0300
3,333,500
160.7600
160.8300
154.0000
155.8200
3,112,400
159.4400
159.4400
157.6000
158.3300
2,855,600
Weekend
Weekend
159.4500
160.0700
158.5300
159.2000
2,121,700
159.8000
160.0500
156.7200
158.7800
3,488,700
159.1200
161.2900
158.5300
160.1200
2,458,400
159.8000
159.9600
156.2600
158.6100
2,050,200
94 · 6-K
After market open · 11:35 ET
ASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT ↗
156.7600
157.2000
154.8100
156.5300
2,256,000
Weekend
Weekend
93 · 6-K
After market open · 10:58 ET
AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY ↗
158.4600
158.8000
156.4100
156.9000
3,035,400
92 · 6-K
After market open · 15:40 ET
ADMISSION OF FURTHER SECURITIES TO TRADING ↗
91 · 6-K
After market open · 15:32 ET
TOTAL VOTING RIGHTS ↗
160.7700
161.3300
157.5400
157.7000
3,377,400
164.4700
164.4800
161.4600
161.4700
2,225,200
90 · 6-K
After market open · 10:41 ET
ASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT ↗
165.0900
166.4700
163.2400
164.2100
3,372,100
165.6900
167.5200
165.3900
166.1500
1,726,600
Weekend
Weekend
166.1600
166.8100
164.6000
166.5800
2,067,900
162.9100
166.2500
162.9100
164.5600
3,188,400
89 · 6-K
After market open · 10:01 ET
TRIXEO APPROVED IN EU FOR ASTHMA ↗
166.5800
167.5900
163.3300
163.3300
2,361,200
167.8400
169.3500
166.7400
168.3700
2,306,200
168.4500
169.0000
167.1100
168.1000
2,937,800
88 · 6-K
Pre-market · 07:04 ET
KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP ↗
87 · 6-K
Pre-market · 06:50 ET
ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC ↗
Weekend
Weekend
86 · 6-K
After market open · 10:33 ET
DIRECTOR/PDMR SHAREHOLDING ↗
167.1500
167.8300
165.5400
166.0800
3,060,300
164.5900
166.2900
164.3000
166.1400
3,807,500
164.2100
165.4200
162.0200
162.8900
3,859,100
85 · 6-K
After market open · 10:24 ET
DIRECTOR/PDMR SHAREHOLDING ↗
84 · 6-K
After market open · 10:01 ET
DIRECTOR/PDMR SHAREHOLDING ↗
161.4200
163.9000
160.7100
161.8500
2,939,400
164.0800
164.5500
162.1400
163.7800
3,093,600
83 · 6-K
Pre-market · 07:36 ET
UPDATE ON SERENA-4 PHASE III TRIAL ↗
Weekend
Weekend
161.4300
161.5100
158.1300
160.1700
2,227,300
157.6800
160.3000
157.2300
159.6400
2,935,300
158.3100
159.1300
156.7400
156.9400
3,873,500
163.9600
163.9600
159.4000
160.0400
5,145,600
82 · 6-K
Pre-market · 09:04 ET
IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG ↗
81 · 6-K
Pre-market · 06:29 ET
ETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER ↗
No trading
Weekend
Weekend
162.8200
163.7800
161.1300
162.7000
3,070,400
165.6400
165.7400
162.2400
164.7700
2,425,200
162.5400
164.6900
160.8700
161.6300
3,300,800
80 · 6-K
After market open · 12:20 ET
ADMISSION OF FURTHER SECURITIES TO TRADING ↗
79 · 6-K
After market open · 12:08 ET
TOTAL VOTING RIGHTS ↗
163.6600
164.2400
161.3900
162.4700
2,598,500
78 · 6-K
Pre-market · 07:36 ET
ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING ↗
77 · 6-K
Pre-market · 07:27 ET
ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC ↗
76 · 6-K
Pre-market · 07:18 ET
DIRECTORATE CHANGE ↗
75 · 6-K
Pre-market · 07:10 ET
ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY ↗
74 · 6-K
Pre-market · 07:04 ET
TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG ↗
162.7000
163.7500
161.9500
162.1300
3,067,800
Weekend
Weekend
163.5200
163.5400
161.1800
162.7000
2,880,700
165.2700
165.5800
163.9800
164.5200
2,495,200
73 · 6-K
Pre-market · 07:04 ET
TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS ↗
167.4600
167.8900
165.1700
166.2700
2,680,600
167.0800
170.1800
166.7800
169.6600
3,453,200
72 · 6-K
Pre-market · 07:03 ET
ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING ↗
164.5700
167.0800
163.9700
166.7100
2,780,100
Weekend
Weekend
164.0400
167.2500
163.9600
165.9800
3,179,600
163.4000
165.5700
161.4800
164.4900
5,094,000
71 · 6-K
After market open · 09:43 ET
DIRECTOR/PDMR SHAREHOLDING ↗
162.1300
165.9100
162.0000
164.9500
3,817,900
159.1200
160.6400
158.9800
160.1000
3,001,300
156.3000
157.2600
155.7800
156.8900
3,361,600
70 · 6-K
Pre-market · 07:15 ET
ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER ↗
69 · 6-K
Pre-market · 07:08 ET
UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL ↗
68 · 6-K
Pre-market · 07:03 ET
TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG ↗
Weekend
Weekend
155.5000
156.4600
154.5300
156.4500
3,697,500
157.8500
158.4400
156.9700
157.2400
3,598,300
157.6800
159.0200
157.1200
158.5000
4,140,400
162.0600
162.2600
158.6100
158.7500
2,754,800
160.5900
162.7200
160.2500
161.9100
3,745,800
Weekend
Weekend
162.1400
162.1800
160.0000
161.4200
3,720,300
162.6200
162.9300
159.7500
161.0700
2,353,900
163.7900
164.4500
160.7200
161.5000
7,002,500
157.9500
158.5600
155.3200
155.6200
8,095,300
67 · 6-K
After market open · 10:44 ET
ADMISSION OF FURTHER SECURITIES TO TRADING ↗
66 · 6-K
After market open · 10:29 ET
TOTAL VOTING RIGHTS ↗
157.1700
159.7200
153.4100
157.9700
16,313,000
Weekend
Weekend
170.5300
170.7400
168.4400
169.6400
1,669,900
65 · 6-K
Pre-market · 06:54 ET
DATROWAY APPROVED IN EU FOR TNBC ↗
170.3200
171.8900
169.8500
171.3400
2,260,600
174.2400
175.0400
172.6300
173.3000
2,252,100
170.7000
174.4400
170.6700
172.4800
4,740,700
170.0800
173.2400
167.7900
169.6400
3,861,200
64 · 6-K
Pre-market · 07:07 ET
UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA ↗
63 · 6-K
Pre-market · 06:56 ET
SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS ↗
62 · 6-K
Pre-market · 07:51 ET
FORM 6-K ↗
Weekend
Weekend
169.8400
170.2600
168.3300
169.2600
2,010,000
166.3700
169.4900
166.0400
168.2700
2,394,100
61 · 6-K
Pre-market · 06:01 ET
ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER ↗
170.6400
170.8900
168.4700
169.7300
1,683,700
165.3500
169.4300
164.8200
169.3400
1,986,000
168.4600
168.6500
164.0600
164.5200
2,552,900
Weekend
Weekend
168.1500
170.3100
167.1500
168.9000
1,981,300
167.9700
170.3700
167.2500
169.2900
3,018,300
166.2200
169.5800
166.2100
168.3700
2,938,200
167.3600
168.1000
164.4500
164.5000
3,605,500
60 · 6-K
Pre-market · 06:37 ET
ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR ↗
168.7500
170.4700
168.1100
169.4700
4,666,100
Weekend
Weekend
175.4900
175.8800
171.4200
171.6100
3,596,900
173.4500
180.2100
172.7600
178.4900
6,649,000
59 · 6-K
Pre-market · 06:17 ET
UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL ↗
189.9500
191.4800
188.6700
189.2800
1,967,800
192.9800
193.7900
191.6000
193.1200
2,130,000
190.2000
190.2400
186.2400
190.1600
1,872,000
Weekend
Weekend
No trading
189.5200
196.4100
189.1700
195.1500
2,379,500
58 · 6-K
After market open · 10:10 ET
ADMISSION OF FURTHER SECURITIES TO TRADING ↗
57 · 6-K
After market open · 10:06 ET
TOTAL VOTING RIGHTS ↗
187.0700
187.6500
183.4900
183.8600
2,115,500
190.3100
190.4600
186.1600
189.6200
2,598,700
189.2500
191.1300
188.4500
190.9500
1,644,300
56 · 6-K
Pre-market · 06:45 ET
ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS ↗
55 · 6-K
Pre-market · 06:05 ET
DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC ↗
Weekend
Weekend
184.2800
189.5700
184.2800
188.4100
3,235,300
184.8200
186.5800
184.5500
185.6800
1,826,200
183.4000
184.6100
182.1900
183.0200
2,377,700
179.8100
181.1500
179.2800
181.0200
1,503,700
175.2900
177.4300
175.1100
176.4300
1,489,600
Weekend
Weekend
No trading
177.6700
177.8000
173.6600
174.9300
1,667,000
178.7000
180.4400
177.6500
177.8900
1,868,700
178.3300
179.1200
176.6400
178.7100
1,895,800
179.1600
179.2200
176.5500
177.2700
1,328,700
54 · 6-K
Pre-market · 06:52 ET
TRUQAP APPROVED IN US FOR PROSTATE CANCER ↗
Weekend
Weekend
182.5300
182.7000
178.5900
178.7500
2,394,100
181.3600
183.6700
180.3900
182.2800
1,749,400
180.9400
181.7200
177.8800
178.9600
2,129,600
181.7300
183.8100
181.1600
183.4300
1,963,700
184.1600
185.3100
181.3600
181.5500
2,040,000
Weekend
Weekend
184.0200
186.1200
184.0200
185.9500
2,346,100
180.5800
183.3700
180.2400
181.8000
2,030,300
174.6000
177.5600
174.6000
176.2800
2,397,000
179.1000
179.5600
176.0300
177.4500
2,035,100
53 · 6-K
After market open · 10:10 ET
ADMISSION OF FURTHER SECURITIES TO TRADING ↗
52 · 6-K
After market open · 10:06 ET
TOTAL VOTING RIGHTS ↗
182.7200
183.2300
179.6200
179.7100
2,892,500
Weekend
Weekend
185.9900
187.1000
184.6500
185.6700
1,499,100
51 · 6-K
Pre-market · 06:43 ET
IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER ↗
183.8000
186.4600
183.3600
185.3300
2,059,500
187.4300
188.7200
185.3800
185.6500
2,121,600
50 · 6-K
Pre-market · 06:04 ET
US FDA DECISION DATE ON CAMIZESTRANT EXTENDED ↗
188.2600
188.6100
186.7400
187.1900
1,411,800
49 · 6-K
Pre-market · 07:17 ET
DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC ↗
48 · 6-K
Pre-market · 07:09 ET
ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS ↗
47 · 6-K
Pre-market · 07:02 ET
CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU ↗
No trading
Weekend
Weekend
188.2200
189.0800
186.4500
187.0300
2,120,800
185.8400
191.5000
184.9800
189.7500
2,192,700
186.6900
188.3100
185.7300
187.4600
1,803,500
184.7000
186.3600
184.1900
184.6400
1,616,800
46 · 6-K
After market open · 10:15 ET
DIRECTOR/PDMR SHAREHOLDING ↗
45 · 6-K
After market open · 09:42 ET
BAXFENDY APPROVED IN THE US FOR HYPERTENSION ↗
44 · 6-K
After market open · 09:36 ET
ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS ↗
183.4300
184.7400
182.6700
183.9200
1,225,200
Weekend
Weekend
183.2500
183.4400
180.5500
181.5800
1,379,300
186.6900
186.7000
184.7000
184.9600
1,027,700
43 · 6-K
Pre-market · 07:25 ET
IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER ↗
183.3600
187.7800
183.3300
187.7200
1,733,000
183.0100
185.8200
182.7000
184.5400
1,595,900
183.7900
185.8100
181.7300
181.8600
2,106,700
Weekend
Weekend
182.7100
183.5500
181.5800
182.8500
1,910,400
184.3700
184.3700
181.0300
182.5200
2,749,500
184.5300
185.6100
183.5500
184.9200
1,953,700
181.4800
181.9800
180.0000
181.2400
2,459,800
184.3600
185.1900
182.8000
183.4600
1,170,100
Weekend
Weekend
42 · 6-K
After market open · 10:23 ET
TOTAL VOTING RIGHTS AND ADMISSION OF SHARES ↗
185.4500
187.1800
184.0100
184.7400
1,793,600
41 · 6-K
Pre-market · 08:45 ET
FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER ↗
40 · 6-K
Pre-market · 08:40 ET
FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER ↗
188.4700
190.0000
186.8700
187.3700
2,797,300
183.9300
187.0000
181.7300
185.2000
4,442,800
39 · 6-K
Pre-market · 07:23 ET
1ST QUARTER RESULTS ↗
186.9100
187.9800
185.4100
186.6800
2,837,100
38 · 6-K
Pre-market · 07:31 ET
BREZTRI APPROVED IN THE US FOR ASTHMA ↗
188.9100
190.5900
187.2000
187.5100
2,102,000
37 · 6-K
Pre-market · 06:29 ET
SAPHNELO SELF-ADMINISTRATION APPROVED IN THE US ↗
Weekend
Weekend
189.1500
189.9400
187.5600
189.7500
2,388,300
195.2100
196.6400
191.8100
192.3000
2,179,300
36 · 6-K
Pre-market · 06:10 ET
DIRECTORATE CHANGE ↗
196.5500
196.6500
194.8000
194.8100
1,578,700
198.8500
198.9900
195.7700
195.7800
2,130,700
35 · 6-K
Pre-market · 06:19 ET
I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINT ↗
202.8100
203.3700
200.6700
200.6900
1,104,500
34 · 6-K
Pre-market · 07:03 ET
THIRD TOZORAKIMAB POSITIVE PHASE III IN COPD ↗
Weekend
Weekend
202.8100
205.3000
202.5500
204.8000
1,241,300
201.4400
201.8000
199.9900
200.4700
1,414,400
204.2000
204.3900
199.5000
201.2100
1,657,800
202.5500
204.7300
202.0700
204.3800
2,257,500
202.4800
203.1800
200.7000
202.2400
1,724,300
Weekend
Weekend
207.3000
207.3000
203.8200
204.0300
1,565,700
33 · 6-K
After market open · 13:01 ET
RESULT OF AGM ↗
202.6400
206.5000
201.9700
204.9900
1,239,200
205.4500
206.7300
203.6600
204.2700
2,282,900
198.7100
202.0000
196.9500
200.8100
2,450,800
204.7500
204.7500
202.7300
202.8300
1,554,700
Weekend
Weekend
No trading
199.7800
204.3400
199.2300
203.4900
2,049,300
32 · 6-K
Pre-market · 09:27 ET
IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER ↗
31 · 6-K
After market open · 10:30 ET
TOTAL VOTING RIGHTS AND ADMISSION OF SHARES ↗
198.8900
201.7400
198.7200
200.7300
2,158,600
194.8500
197.2700
193.5500
197.2200
2,759,600
30 · 6-K
Pre-market · 07:48 ET
EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS ↗
193.8300
194.6400
192.6100
193.8800
2,113,900
Weekend
Weekend
190.8800
192.9700
187.9500
188.4200
2,762,900
29 · 6-K
Pre-market · 08:04 ET
TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS ↗
185.0800
186.8100
182.7900
183.4000
1,850,300
187.6700
188.7200
186.4400
187.1400
1,484,000
182.6300
186.2200
182.3900
185.7800
1,596,200
183.8600
186.7800
183.7600
184.0700
2,009,400
Weekend
Weekend
188.1400
188.4000
182.6200
183.6000
2,068,000
28 · 6-K
Pre-market · 07:59 ET
NOTIFICATION OF ADMISSION OF SHARES ↗
186.7300
189.7900
186.3300
188.9300
1,469,900
190.6700
190.7300
187.5600
188.4200
1,174,400
193.9600
193.9600
190.9500
191.2900
1,455,600
190.8100
192.5100
190.5400
192.0100
1,828,800
27 · 6-K
Pre-market · 08:45 ET
IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER ↗
Weekend
Weekend
192.6400
193.6500
189.4300
189.9000
1,429,000
193.9100
193.9200
190.9600
192.5000
2,154,800
194.2200
194.8300
192.3100
193.3100
1,416,800
196.7200
198.0900
194.8100
194.9900
1,658,200
26 · 6-K
Pre-market · 08:07 ET
NOTICE OF AGM ↗
25 · 6-K
Pre-market · 07:37 ET
FORM 6-K ↗
190.3300
195.7900
189.3500
194.9500
1,875,000
Weekend
Weekend
194.0100
194.8300
192.7600
194.2200
1,473,800
24 · 6-K
Pre-market · 08:11 ET
DIRECTOR/PDMR SHAREHOLDING ↗
23 · 6-K
Pre-market · 07:50 ET
DIRECTOR/PDMR SHAREHOLDING ↗
22 · 6-K
Pre-market · 07:43 ET
DIRECTOR/PDMR SHAREHOLDING ↗
199.4000
199.5200
195.2600
197.5200
2,648,600
203.2200
203.2900
200.5500
201.5300
2,911,100
200.0000
201.9900
197.1000
201.7600
2,733,100
21 · 6-K
After market open · 12:00 ET
TOTAL VOTING RIGHTS ↗
20 · 6-K
After-hours · 16:05 ET
FORM 6-K ↗
205.6400
206.3000
203.3400
203.7300
1,718,800
Weekend
Weekend
19 · 424B2
After-hours · 16:05 ET
424B2 ↗
207.2700
209.9300
206.9500
208.4500
1,996,300
204.9800
205.1600
202.6400
203.9800
2,250,400
18 · 6-K
Pre-market · 08:59 ET
ASTRAZENECA PRICES A $2BN BOND OFFERING ↗
17 · 6-K
After market open · 10:40 ET
FILING OF FORM 20-F WITH SEC ↗
206.7500
207.5500
205.3000
205.7900
1,434,800
16 · 424B2
Pre-market · 08:30 ET
424B2 ↗
13 · 20-F
After-hours · 16:17 ET
20-F ↗
12 · 6-K
After-hours · 16:06 ET
FORM 6-K ↗
208.9900
209.3500
206.4900
206.6100
1,710,800
15 · 6-K
Pre-market · 06:51 ET
ANNUAL FINANCIAL REPORT ↗
14 · 6-K
Pre-market · 06:45 ET
DIRECTORATE CHANGE ↗
204.6000
207.3400
204.2600
204.9400
1,815,400
Weekend
Weekend
206.6000
207.6900
204.0500
204.2000
1,592,700
11 · 6-K
Pre-market · 06:57 ET
FIXED-DURATION CALQUENCE COMBO APPROVED IN US ↗
208.7500
208.9500
205.7200
208.6200
2,036,900
212.6600
212.7100
207.5200
208.6700
2,604,100
208.1000
211.2700
207.8500
209.4800
2,287,700
No trading
Weekend
Weekend
205.6400
206.7100
204.0900
205.5500
2,504,800
202.5200
205.8600
202.1000
204.5200
2,723,800
200.0800
204.9200
199.1900
204.7600
3,483,900
10 · 6-K
After market open · 11:55 ET
FINAL RESULTS ↗
194.0200
195.9000
190.6000
193.4000
2,726,400
191.8000
192.7600
187.0600
188.0100
3,030,400
Weekend
Weekend
190.4600
193.9700
188.4900
193.0300
3,117,300
187.0700
190.6700
186.5800
187.1600
3,380,500
189.0600
190.7000
186.3200
187.4500
3,889,200
187.6100
190.7200
183.6300
184.3200
2,659,700
9 · 6-K
Pre-market · 07:01 ET
UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION ↗
8 · 6-K
After market open · 13:26 ET
TOTAL VOTING RIGHTS ↗
190.4400
192.7900
186.1800
188.4100
3,228,800
7 · 6-K
Pre-market · 07:51 ET
IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER ↗
6 · 6-K
Pre-market · 07:25 ET
ASTRAZENECA BEGINS TRADING ON NYSE ↗
Weekend
Weekend
186.0600
187.0200
184.9200
185.5400
2,777,500
5 · 6-K
Pre-market · 06:19 ET
ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC ↗
186.7400
187.0600
185.1400
185.1800
3,237,350
4 · 6-K
Pre-market · 08:08 ET
ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030 ↗
186.3400
187.6800
185.8000
186.4400
4,117,150
189.3000
192.3600
189.3000
191.2000
3,526,350
186.2800
189.1800
186.1600
188.4600
3,054,100
Weekend
Weekend
184.1200
185.9800
182.8800
185.9000
2,161,400
180.9000
183.5800
180.3400
183.3800
3,072,600
179.3600
181.5800
178.0800
181.0800
4,558,000
180.2800
182.2400
178.3400
179.8800
5,568,650
3 · 6-K
Pre-market · 07:18 ET
ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE ↗
No trading
Weekend
Weekend
188.9400
189.3600
187.0200
188.7800
27,525,250
190.6000
190.7200
186.8200
187.9800
4,573,200
192.0400
192.8600
190.7400
192.6800
3,854,650
188.2800
189.0800
185.5600
189.0200
4,018,600
190.2800
190.3600
186.8200
187.2600
5,377,550
Weekend
Weekend
190.4800
191.8800
189.0800
189.3000
3,038,700
190.3600
191.9000
186.4400
188.0200
2,808,100
2 · 6-K
Pre-market · 06:04 ET
AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON ↗
189.6200
193.0200
188.2400
190.3200
3,307,450
184.9800
190.5400
184.9200
189.9200
3,162,450
182.3400
182.7600
179.0600
182.4400
2,954,200
Weekend
Weekend
1 · 6-K
After market open · 12:24 ET
TOTAL VOTING RIGHTS ↗
184.7800
184.9000
182.3400
183.1400
1,781,600
No trading
184.5000
184.9600
183.8400
183.8600
1,048,650
185.3200
185.7600
184.7200
185.0200
865,100
184.6600
185.7800
184.6600
185.0400
1,185,900
Weekend
Weekend
185.0600
185.8200
184.3600
185.8000
834,700
No trading
184.6400
185.2200
184.0200
184.9000
592,350
185.0400
186.2000
183.8800
184.2800
1,772,200
181.6200
183.7200
181.2600
183.1000
2,324,500
Weekend
Weekend
180.8600
183.7400
180.7200
182.7200
4,187,150
180.5800
182.3400
180.3800
181.2200
3,414,250
182.1800
182.5000
179.7000
179.7200
2,987,750
181.7400
183.1600
180.3800
182.7000
2,257,450
180.7400
183.5800
180.2400
183.1200
3,510,200
Weekend
Weekend
178.8000
179.9200
178.5600
179.6600
2,688,650
181.2400
183.0400
180.4000
180.5800
3,313,950
182.3600
183.3200
179.4000
183.0200
3,059,950
182.3600
182.9000
179.5600
179.6400
2,363,900
180.7400
182.7400
179.3400
182.5600
3,527,750
Weekend
Weekend
181.3800
182.3600
180.1400
180.3600
2,716,450
181.3000
181.7400
179.5400
180.0600
2,625,450
181.3800
182.5600
181.0400
181.7000
3,418,500
181.8200
182.1600
180.2800
180.3400
3,252,350
185.8800
185.9600
180.8600
181.0400
3,183,300
Weekend
Weekend
185.1400
185.6600
184.1000
185.4400
1,874,000
No trading
186.0000
188.0400
185.6800
186.6400
2,328,000
184.8800
186.8200
184.4000
186.4800
2,712,750
181.2200
183.6600
181.2200
183.0400
2,863,100
Weekend
Weekend
178.6800
183.8200
178.6800
182.0000
3,701,150
179.7000
180.0200
176.8200
177.3600
2,931,500
179.1200
180.1400
177.1800
177.9800
3,219,300
178.0600
179.4200
176.8800
179.1000
3,178,950
178.6600
180.5400
178.2400
178.8000
1,907,050
Weekend
Weekend
177.0400
178.7400
176.5600
178.2000
2,045,200
175.7800
178.8600
175.2400
177.2200
2,257,200
176.5400
177.8000
174.4600
175.3600
2,615,800
176.3800
178.6400
176.0000
178.1800
2,481,600
172.4800
175.0600
171.7000
174.9600
3,135,700
Weekend
Weekend
169.1000
170.3000
168.4400
169.1600
2,052,900
168.6200
170.0400
166.7400
167.5400
3,471,050
162.7600
164.1800
162.0400
162.3000
2,724,400
161.3000
164.2200
160.9600
164.0600
2,336,600
163.9600
164.8000
162.1000
163.4400
1,448,050
Weekend
Weekend
164.3600
165.1000
163.0000
164.8000
1,488,850
164.1800
165.6400
162.5800
164.6800
2,895,650
166.7800
166.9200
163.2800
164.4600
1,784,800
168.0800
168.4400
163.5600
165.2200
1,830,750
166.9200
168.4200
166.4800
168.1200
3,123,950
Weekend
Weekend
166.9000
167.0400
165.8400
166.5800
1,190,200
166.3400
167.6200
166.2400
166.8000
1,074,800
Announcement Events
Each title opens the filing on the SEC website. Registered users can summarise the filing and up to seven relevant exhibits linked within the same SEC submission.
95
6-K
ULTOMIRIS APPROVED IN US IN IGAN (opens SEC filing in a new tab)
After market open · 11:10 ET
Summarise
94
6-K
ASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT (opens SEC filing in a new tab)
After market open · 11:35 ET
Summarise
93
6-K
AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY (opens SEC filing in a new tab)
After market open · 10:58 ET
Summarise
92
6-K
ADMISSION OF FURTHER SECURITIES TO TRADING (opens SEC filing in a new tab)
After market open · 15:40 ET
Summarise
90
6-K
ASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT (opens SEC filing in a new tab)
After market open · 10:41 ET
Summarise
89
6-K
TRIXEO APPROVED IN EU FOR ASTHMA (opens SEC filing in a new tab)
After market open · 10:01 ET
Summarise
88
6-K
KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP (opens SEC filing in a new tab)
Pre-market · 07:04 ET
Summarise
87
6-K
ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC (opens SEC filing in a new tab)
Pre-market · 06:50 ET
Summarise
86
6-K
DIRECTOR/PDMR SHAREHOLDING (opens SEC filing in a new tab)
After market open · 10:33 ET
Summarise
85
6-K
DIRECTOR/PDMR SHAREHOLDING (opens SEC filing in a new tab)
After market open · 10:24 ET
Summarise
84
6-K
DIRECTOR/PDMR SHAREHOLDING (opens SEC filing in a new tab)
After market open · 10:01 ET
Summarise
83
6-K
UPDATE ON SERENA-4 PHASE III TRIAL (opens SEC filing in a new tab)
Pre-market · 07:36 ET
Summarise
82
6-K
IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG (opens SEC filing in a new tab)
Pre-market · 09:04 ET
Summarise
81
6-K
ETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER (opens SEC filing in a new tab)
Pre-market · 06:29 ET
Summarise
80
6-K
ADMISSION OF FURTHER SECURITIES TO TRADING (opens SEC filing in a new tab)
After market open · 12:20 ET
Summarise
78
6-K
ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING (opens SEC filing in a new tab)
Pre-market · 07:36 ET
Summarise
77
6-K
ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC (opens SEC filing in a new tab)
Pre-market · 07:27 ET
Summarise
75
6-K
ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY (opens SEC filing in a new tab)
Pre-market · 07:10 ET
Summarise
74
6-K
TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG (opens SEC filing in a new tab)
Pre-market · 07:04 ET
Summarise
73
6-K
TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS (opens SEC filing in a new tab)
Pre-market · 07:04 ET
Summarise
72
6-K
ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING (opens SEC filing in a new tab)
Pre-market · 07:03 ET
Summarise
71
6-K
DIRECTOR/PDMR SHAREHOLDING (opens SEC filing in a new tab)
After market open · 09:43 ET
Summarise
70
6-K
ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER (opens SEC filing in a new tab)
Pre-market · 07:15 ET
Summarise
69
6-K
UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL (opens SEC filing in a new tab)
Pre-market · 07:08 ET
Summarise
68
6-K
TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG (opens SEC filing in a new tab)
Pre-market · 07:03 ET
Summarise
67
6-K
ADMISSION OF FURTHER SECURITIES TO TRADING (opens SEC filing in a new tab)
After market open · 10:44 ET
Summarise
65
6-K
DATROWAY APPROVED IN EU FOR TNBC (opens SEC filing in a new tab)
Pre-market · 06:54 ET
Summarise
64
6-K
UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA (opens SEC filing in a new tab)
Pre-market · 07:07 ET
Summarise
63
6-K
SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS (opens SEC filing in a new tab)
Pre-market · 06:56 ET
Summarise
61
6-K
ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER (opens SEC filing in a new tab)
Pre-market · 06:01 ET
Summarise
60
6-K
ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR (opens SEC filing in a new tab)
Pre-market · 06:37 ET
Summarise
59
6-K
UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL (opens SEC filing in a new tab)
Pre-market · 06:17 ET
Summarise
58
6-K
ADMISSION OF FURTHER SECURITIES TO TRADING (opens SEC filing in a new tab)
After market open · 10:10 ET
Summarise
56
6-K
ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS (opens SEC filing in a new tab)
Pre-market · 06:45 ET
Summarise
55
6-K
DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC (opens SEC filing in a new tab)
Pre-market · 06:05 ET
Summarise
54
6-K
TRUQAP APPROVED IN US FOR PROSTATE CANCER (opens SEC filing in a new tab)
Pre-market · 06:52 ET
Summarise
53
6-K
ADMISSION OF FURTHER SECURITIES TO TRADING (opens SEC filing in a new tab)
After market open · 10:10 ET
Summarise
51
6-K
IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER (opens SEC filing in a new tab)
Pre-market · 06:43 ET
Summarise
50
6-K
US FDA DECISION DATE ON CAMIZESTRANT EXTENDED (opens SEC filing in a new tab)
Pre-market · 06:04 ET
Summarise
49
6-K
DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC (opens SEC filing in a new tab)
Pre-market · 07:17 ET
Summarise
48
6-K
ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS (opens SEC filing in a new tab)
Pre-market · 07:09 ET
Summarise
47
6-K
CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU (opens SEC filing in a new tab)
Pre-market · 07:02 ET
Summarise
46
6-K
DIRECTOR/PDMR SHAREHOLDING (opens SEC filing in a new tab)
After market open · 10:15 ET
Summarise
45
6-K
BAXFENDY APPROVED IN THE US FOR HYPERTENSION (opens SEC filing in a new tab)
After market open · 09:42 ET
Summarise
44
6-K
ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS (opens SEC filing in a new tab)
After market open · 09:36 ET
Summarise
43
6-K
IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER (opens SEC filing in a new tab)
Pre-market · 07:25 ET
Summarise
42
6-K
TOTAL VOTING RIGHTS AND ADMISSION OF SHARES (opens SEC filing in a new tab)
After market open · 10:23 ET
Summarise
41
6-K
FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER (opens SEC filing in a new tab)
Pre-market · 08:45 ET
Summarise
40
6-K
FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER (opens SEC filing in a new tab)
Pre-market · 08:40 ET
Summarise
38
6-K
BREZTRI APPROVED IN THE US FOR ASTHMA (opens SEC filing in a new tab)
Pre-market · 07:31 ET
Summarise
37
6-K
SAPHNELO SELF-ADMINISTRATION APPROVED IN THE US (opens SEC filing in a new tab)
Pre-market · 06:29 ET
Summarise
35
6-K
I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINT (opens SEC filing in a new tab)
Pre-market · 06:19 ET
Summarise
34
6-K
THIRD TOZORAKIMAB POSITIVE PHASE III IN COPD (opens SEC filing in a new tab)
Pre-market · 07:03 ET
Summarise
32
6-K
IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER (opens SEC filing in a new tab)
Pre-market · 09:27 ET
Summarise
31
6-K
TOTAL VOTING RIGHTS AND ADMISSION OF SHARES (opens SEC filing in a new tab)
After market open · 10:30 ET
Summarise
30
6-K
EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS (opens SEC filing in a new tab)
Pre-market · 07:48 ET
Summarise
29
6-K
TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS (opens SEC filing in a new tab)
Pre-market · 08:04 ET
Summarise
28
6-K
NOTIFICATION OF ADMISSION OF SHARES (opens SEC filing in a new tab)
Pre-market · 07:59 ET
Summarise
27
6-K
IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER (opens SEC filing in a new tab)
Pre-market · 08:45 ET
Summarise
18
6-K
ASTRAZENECA PRICES A $2BN BOND OFFERING (opens SEC filing in a new tab)
Pre-market · 08:59 ET
Summarise
17
6-K
FILING OF FORM 20-F WITH SEC (opens SEC filing in a new tab)
After market open · 10:40 ET
Summarise
11
6-K
FIXED-DURATION CALQUENCE COMBO APPROVED IN US (opens SEC filing in a new tab)
Pre-market · 06:57 ET
Summarise
9
6-K
UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION (opens SEC filing in a new tab)
Pre-market · 07:01 ET
Summarise
7
6-K
IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER (opens SEC filing in a new tab)
Pre-market · 07:51 ET
Summarise
6
6-K
ASTRAZENECA BEGINS TRADING ON NYSE (opens SEC filing in a new tab)
Pre-market · 07:25 ET
Summarise
5
6-K
ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC (opens SEC filing in a new tab)
Pre-market · 06:19 ET
Summarise
4
6-K
ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030 (opens SEC filing in a new tab)
Pre-market · 08:08 ET
Summarise
3
6-K
ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE (opens SEC filing in a new tab)
Pre-market · 07:18 ET
Summarise